UK/DE/US

Management

MANAGEMENT

Prof. Dr. rer. nat. Hermann Lübbert, CEO

Prof. Hermann Lübbert, PhD, is Chief Executive Officer of Biofrontera AG and Managing Director of all its subsidiaries. He studied biology in his native city of Cologne, where he completed a PhD in 1984.

After eight years of academic research at the University of Cologne and the California Institute of Technology (USA), he was awarded the habilitation at the ETH (Eidgenössische Technische Hochschule) Zürich. Prof. Lübbert has held the Chair of Animal Physiology at Ruhr-University Bochum since 1998. During his ten years at Sandoz and Novartis Pharma AG, Prof. Lübbert acquired experience in managing a globally active research organisation.

He founded Biofrontera in 1997 and has since managed the company.

Thomas Schaffer, CFO

Thomas Schaffer started his career in various functions in Finance and Controlling at Siemens Semiconductor, where he reached the position of Vice President and CFO of the Security & Chipcard ICs.

After four years as Managing Director and CFO of Infineon Ventures GmbH, he continued as Vice President and CFO of the Specialty DRAM Division of Qimonda AG and became Managing Director of Qimonda Solar GmbH. CFO positions at Heptagon Oy, Finland/Switzerland, and Ubidyne Inc., Delaware, USA, completed his strong international experience.

Mr. Schaffer has been the CFO of Biofrontera AG since June 2013.

Christoph Dünwald, CCO

Christoph Dünwald began his professional career at Bayer, where he worked for 15 years in positions of increasing responsibility in Marketing in both Spain and the US, as well as in Strategic Management positions in Germany and Asia Pacific.

He then oversaw Bayer’s Healthcare Diagnostics Division in Belgium and Luxembourg as the General Manager. Following two years as International Sales and Marketing Director for Corporación Dermoestética SA in Spain and the UK he moved on to the US pharmaceutical company Allergan as Senior Commercial Director. From 2009 until 2015, he was assigned the responsibility for Allergan’s Medical Business Unit in Spain and Portugal.

He has been responsible for marketing and sales as well as for the further development of the US business at Biofrontera since 2016.